# reload+after+2024-01-23 09:43:49.685535
address1§555 Long Wharf Drive
address2§12th Floor
city§New Haven
state§CT
zip§06511
country§United States
phone§475 238 6837
website§https://www.bioxceltherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
fullTimeEmployees§183
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Vimal D. Mehta Ph.D.', 'age': 62, 'title': 'Founder, CEO, President, & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 1764523, 'exercisedValue': 0, 'unexercisedValue': 10870268}, {'maxAge': 1, 'name': 'Mr. Javier  Rodriguez', 'age': 51, 'title': 'Senior VP, Chief Legal Officer & Corporate Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 638881, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew  Wiley', 'age': 51, 'title': 'Senior VP & Chief Commercial Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 620125, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard I. Steinhart MBA', 'age': 66, 'title': 'Senior VP & CFO', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 403997, 'exercisedValue': 0, 'unexercisedValue': 463292}, {'maxAge': 1, 'name': 'Dr. Frank D. Yocca Ph.D.', 'age': 67, 'title': 'Senior VP & Chief Scientific Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 452582, 'exercisedValue': 0, 'unexercisedValue': 1401100}, {'maxAge': 1, 'name': "Dr. Vincent J. O'Neill B.Sc., M.D., M.R.C.P.", 'age': 54, 'title': 'Executive VP, Chief of Product Development & Medical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 510167, 'exercisedValue': 0, 'unexercisedValue': 1073382}, {'maxAge': 1, 'name': 'Dr. Chetan D. Lathia Ph.D.', 'title': 'Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert  Risinger M.D.', 'title': 'Chief Medical Officer - Neuroscience', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Scala', 'age': 54, 'title': 'Vice President of Commercial Operations & Launch Planning', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Friso  Postma', 'title': 'Senior Director of Neuroscience & Artificial intelligence', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§7
compensationRisk§8
shareHolderRightsRisk§6
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.615
priceToSalesTrailing12Months§66.2289
currency§USD
dateShortInterest§1702598400
forwardEps§-2.51
pegRatio§0.0
exchange§NCM
quoteType§EQUITY
shortName§BioXcel Therapeutics, Inc.
longName§BioXcel Therapeutics, Inc.
firstTradeDateEpochUtc§1520519400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ed3396e0-a498-379a-b23a-cf6795d0f871
gmtOffSetMilliseconds§-18000000
targetHighPrice§25.0
targetLowPrice§4.0
targetMeanPrice§14.0
targetMedianPrice§11.5
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§2.301
grossMargins§0.55314
ebitdaMargins§0.0
trailingPegRatio§None
